These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 29228933)

  • 1. Pulmonary exacerbations and clinical outcomes in a longitudinal cohort of infants and preschool children with cystic fibrosis.
    Hoppe JE; Wagner BD; Sagel SD; Accurso FJ; Zemanick ET
    BMC Pulm Med; 2017 Dec; 17(1):188. PubMed ID: 29228933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pulmonary exacerbations and acute declines in lung function in patients with cystic fibrosis.
    Wagener JS; Williams MJ; Millar SJ; Morgan WJ; Pasta DJ; Konstan MW
    J Cyst Fibros; 2018 Jul; 17(4):496-502. PubMed ID: 29685810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibiotic treatment of signs and symptoms of pulmonary exacerbations: a comparison by care site.
    Schechter MS; Regelmann WE; Sawicki GS; Rasouliyan L; VanDevanter DR; Rosenfeld M; Pasta D; Morgan W; Konstan MW
    Pediatr Pulmonol; 2015 May; 50(5):431-40. PubMed ID: 25530325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SPLUNC1 as a biomarker of pulmonary exacerbations in children with cystic fibrosis.
    Ben-Meir E; Perrem L; Shaw M; Ratjen F; Grasemann H
    J Cyst Fibros; 2024 Mar; 23(2):288-292. PubMed ID: 38413298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics and outcomes of oral antibiotic treated pulmonary exacerbations in children with cystic fibrosis.
    Hoppe JE; Wagner BD; Accurso FJ; Zemanick ET; Sagel SD
    J Cyst Fibros; 2018 Nov; 17(6):760-768. PubMed ID: 29921503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis.
    Heltshe SL; Goss CH; Thompson V; Sagel SD; Sanders DB; Marshall BC; Flume PA
    Thorax; 2016 Mar; 71(3):223-9. PubMed ID: 25911223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibiotic duration and changes in FEV
    Espel JC; Palac HL; Cullina JF; Clarke AP; McColley SA; Prickett MH; Jain M
    BMC Pulm Med; 2017 Nov; 17(1):160. PubMed ID: 29187171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale and design of a randomized trial of home electronic symptom and lung function monitoring to detect cystic fibrosis pulmonary exacerbations: the early intervention in cystic fibrosis exacerbation (eICE) trial.
    Lechtzin N; West N; Allgood S; Wilhelm E; Khan U; Mayer-Hamblett N; Aitken ML; Ramsey BW; Boyle MP; Mogayzel PJ; Goss CH
    Contemp Clin Trials; 2013 Nov; 36(2):460-9. PubMed ID: 24055998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for lung disease progression in children with cystic fibrosis.
    van Horck M; van de Kant K; Winkens B; Wesseling G; Gulmans V; Hendriks H; van der Grinten C; Jöbsis Q; Dompeling E
    Eur Respir J; 2018 Jun; 51(6):. PubMed ID: 29773689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating FEV1 decline in diagnosis and management of pulmonary exacerbations in children with cystic fibrosis.
    Bouzek DC; Ren CL; Thompson M; Slaven JE; Sanders DB
    Pediatr Pulmonol; 2022 Jul; 57(7):1709-1716. PubMed ID: 35429154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Lung Clearance Index and Magnetic Resonance Imaging for Assessment of Lung Disease in Children with Cystic Fibrosis.
    Stahl M; Wielpütz MO; Graeber SY; Joachim C; Sommerburg O; Kauczor HU; Puderbach M; Eichinger M; Mall MA
    Am J Respir Crit Care Med; 2017 Feb; 195(3):349-359. PubMed ID: 27575911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations.
    West NE; Beckett VV; Jain R; Sanders DB; Nick JA; Heltshe SL; Dasenbrook EC; VanDevanter DR; Solomon GM; Goss CH; Flume PA;
    J Cyst Fibros; 2017 Sep; 16(5):600-606. PubMed ID: 28457954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pulmonary exacerbation risk score among cystic fibrosis patients not receiving recommended care.
    Sawicki GS; Ayyagari R; Zhang J; Signorovitch JE; Fan L; Swallow E; Latremouille-Viau D; Wu EQ; Shi L
    Pediatr Pulmonol; 2013 Oct; 48(10):954-61. PubMed ID: 23255309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibiotic Regimen Changes during Cystic Fibrosis Pediatric Pulmonary Exacerbation Treatment.
    Cogen JD; Sanders DB; Slaven JE; Faino AV; Somayaji R; Gibson RL; Hoffman LR; Ren CL
    Ann Am Thorac Soc; 2023 Sep; 20(9):1293-1298. PubMed ID: 37327485
    [No Abstract]   [Full Text] [Related]  

  • 15. Prospective evaluation of respiratory exacerbations in children with cystic fibrosis from newborn screening to 5 years of age.
    Byrnes CA; Vidmar S; Cheney JL; Carlin JB; Armstrong DS; Cooper PJ; Grimwood K; Moodie M; Robertson CF; Rosenfeld M; Tiddens HA; Wainwright CE;
    Thorax; 2013 Jul; 68(7):643-51. PubMed ID: 23345574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cystic Fibrosis Pulmonary Exacerbations Attributable to Respiratory Syncytial Virus and Influenza: A Population-Based Study.
    Somayaji R; Goss CH; Khan U; Neradilek M; Neuzil KM; Ortiz JR
    Clin Infect Dis; 2017 Jun; 64(12):1760-1767. PubMed ID: 28329304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic Corticosteroids in the Management of Pediatric Cystic Fibrosis Pulmonary Exacerbations.
    Davis CS; Faino AV; Onchiri F; Gibson RL; Merjaneh L; Ramsey BW; Rosenfeld M; Cogen JD
    Ann Am Thorac Soc; 2023 Jan; 20(1):75-82. PubMed ID: 36044723
    [No Abstract]   [Full Text] [Related]  

  • 18. Improvement in pulmonary function following antibiotics in infants with cystic fibrosis.
    Pittman JE; Johnson RC; Davis SD
    Pediatr Pulmonol; 2012 May; 47(5):441-6. PubMed ID: 22009796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative chest computerized tomography and FEV
    Sanders DB; Li Z; Parker-McGill K; Farrell P; Brody AS
    Pediatr Pulmonol; 2018 Oct; 53(10):1369-1377. PubMed ID: 30160050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poor recovery from cystic fibrosis pulmonary exacerbations is associated with poor long-term outcomes.
    Sanders DB; Zhao Q; Li Z; Farrell PM
    Pediatr Pulmonol; 2017 Oct; 52(10):1268-1275. PubMed ID: 28881091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.